These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31286139)

  • 21. Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
    Kwon OC; Hong S; Ghang B; Kim YG; Lee CK; Yoo B
    Am J Med; 2017 May; 130(5):583-587. PubMed ID: 28065770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of colchicine toxicity in patients with gout.
    Dalbeth N; Gow P
    N Z Med J; 2007 Apr; 120(1252):U2503. PubMed ID: 17460750
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative efficacy of low-dose versus regular-dose colchicine to prevent flares in gout patients initiated on urate-lowering therapies.
    Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Kim YG
    Rheumatology (Oxford); 2021 Dec; 61(1):223-229. PubMed ID: 33764413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
    Kim JW; Kwak SG; Park SH
    Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of gout patients with impairment of renal function: a systematic literature review.
    van Echteld IA; van Durme C; Falzon L; Landewé RB; van der Heijde DM; Aletaha D
    J Rheumatol Suppl; 2014 Sep; 92():48-54. PubMed ID: 25180128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colchicine prescribing in patients with gout.
    Dalbeth N; Gow P;
    N Z Med J; 2011 Jul; 124(1339):107-8. PubMed ID: 21952339
    [No Abstract]   [Full Text] [Related]  

  • 27. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
    Schlesinger N; Mysler E; Lin HY; De Meulemeester M; Rovensky J; Arulmani U; Balfour A; Krammer G; Sallstig P; So A
    Ann Rheum Dis; 2011 Jul; 70(7):1264-71. PubMed ID: 21540198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study.
    Kok VC; Horng JT; Chang WS; Hong YF; Chang TH
    PLoS One; 2014; 9(6):e99102. PubMed ID: 24897240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization patterns of antihyperuricemic agents following safety announcement on allopurinol and benzbromarone by Taiwan Food and Drug Administration.
    Cheng CL; Chao PH; Hsu JC; Weng MM; On AW; Yang YH
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):309-13. PubMed ID: 24307655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study.
    Shih HJ; Kao MC; Tsai PS; Fan YC; Huang CJ
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):328-333. PubMed ID: 28398294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of intravenous colchicine in patients with acute gout.
    Stephan WH
    Am Fam Physician; 2000 Apr; 61(8):2343-4. PubMed ID: 10794578
    [No Abstract]   [Full Text] [Related]  

  • 33. An abnormal elevation of serum CA72-4 rather than other tumor markers can be caused by use of colchicine.
    Zhao B; Zhang M; Liang Y; Yang Z
    Int J Biol Markers; 2019 Sep; 34(3):318-321. PubMed ID: 31507249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dangers of low-dose colchicine in patients with renal failure.
    Prescrire Int; 2000 Aug; 9(48):116. PubMed ID: 11067723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary epidemiology of gout in the UK general population.
    Cea Soriano L; Rothenbacher D; Choi HK; García Rodríguez LA
    Arthritis Res Ther; 2011 Mar; 13(2):R39. PubMed ID: 21371293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis.
    Kuo CF; Grainge MJ; Mallen C; Zhang W; Doherty M
    Rheumatology (Oxford); 2015 Dec; 54(12):2145-50. PubMed ID: 26170376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Summary of the Dutch College of General Practitioners' "Gout" Standard].
    Romeijnders AC; Gorter KJ
    Ned Tijdschr Geneeskd; 2002 Feb; 146(7):309-13. PubMed ID: 11876034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colchicine for the treatment of gout.
    Richette P; Bardin T
    Expert Opin Pharmacother; 2010 Dec; 11(17):2933-8. PubMed ID: 21050036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allopurinol and the incidence of bladder cancer: a Taiwan national retrospective cohort study.
    Chen CJ; Hsieh MC; Liao WT; Chan YT; Chang SJ
    Eur J Cancer Prev; 2016 May; 25(3):216-23. PubMed ID: 25830898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of gout.
    Cohen MG
    Intern Med J; 2011 Jan; 41(1a):70-1. PubMed ID: 21265967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.